HC Wainwright Issues Optimistic Forecast for CRBU Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – HC Wainwright raised their Q2 2025 earnings estimates for shares of Caribou Biosciences in a research report issued to clients and investors on Monday, April 28th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.35) per share for the quarter, up from their previous forecast of ($0.47). HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Caribou Biosciences’ Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.33) EPS and FY2025 earnings at ($1.43) EPS.

Separately, Bank of America decreased their target price on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average price target of $9.33.

Caribou Biosciences Stock Performance

Caribou Biosciences stock opened at $0.80 on Thursday. The company’s 50 day simple moving average is $0.93 and its 200-day simple moving average is $1.51. Caribou Biosciences has a 1 year low of $0.66 and a 1 year high of $3.93. The company has a market capitalization of $74.57 million, a price-to-earnings ratio of -0.49 and a beta of 2.36.

Caribou Biosciences (NASDAQ:CRBU) last issued its quarterly earnings data on Monday, March 10th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.01. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The company had revenue of $2.08 million during the quarter, compared to analyst estimates of $2.11 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Centric Wealth Management acquired a new stake in Caribou Biosciences in the 4th quarter valued at about $27,000. Cerity Partners LLC lifted its stake in Caribou Biosciences by 163.6% in the first quarter. Cerity Partners LLC now owns 40,722 shares of the company’s stock worth $37,000 after acquiring an additional 25,271 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in Caribou Biosciences by 859.0% during the 4th quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company’s stock worth $38,000 after acquiring an additional 21,416 shares in the last quarter. MetLife Investment Management LLC raised its holdings in shares of Caribou Biosciences by 60.0% in the 4th quarter. MetLife Investment Management LLC now owns 24,404 shares of the company’s stock valued at $39,000 after purchasing an additional 9,148 shares in the last quarter. Finally, Diametric Capital LP purchased a new stake in shares of Caribou Biosciences during the 4th quarter worth $42,000. 77.51% of the stock is currently owned by hedge funds and other institutional investors.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.